Lithium treatment response has been suggested to run in families, indicating that genetic variations may play a role in the differences in how individuals respond to treatment. Identifying these genetic factors could lead to the development of new treatments for bipolar disorder and allow for more personalized matching of patients to therapies.
However, as genome-wide association studies (GWAS) have become more common, the risks of both type I and type II errors in genetic association studies have become increasingly clear. To mitigate these risks, larger sample sizes and replication cohorts are essential, followed by pooling data or using meta-analytic techniques. The challenge of obtaining long-term treatment data to accurately define treatment response underscores the importance of collaborative efforts in this field.
This collaboration aims to enable high-quality, well-powered analyses of lithium treatment response data. Following an initial brainstorming session at the 21st conference of the International Group for the Study of Lithium Treated Patients (IGSLi) held in Dresden, Germany, from September 27th to 30th, 2007, ConLiGen was founded by Thomas G. Schulze and Francis J. McMahon at the NIMH Intramural Program after a meeting at NIMH on May 6, 2008.
© 2025 Igsli – Designet af Aveo web&marketing
